04 Jun Bundibugyo Virus: What to Know About the Current Ebola Outbreak
MedicalResearch.com Interview with:
Dr. Kuppalli
Krutika Kuppalli, M.D., FIDSA
Associate Professor, Department of Internal Medicine
Division of Infectious Diseases and Geographic Medicine
Peter O’Donnell School of Public Health
UT Southwestern Medical Center
Dallas, Texas
MedicalResearch.com: What are the characteristics of the Bundibugyo strain of orthoebolavirus? Does it have a natural host vector? How is it transmitted to or between humans?
Response: Bundibugyo virus (BDBV) is one of several species within the genus Orthoebolavirus that can cause Ebola virus disease in humans. It was first identified during an outbreak in Uganda’s Bundibugyo District in 2007. While it is less well known than Zaire ebolavirus—the species responsible for the large West African epidemic—it can still cause severe disease and significant outbreaks.
Like other ebolaviruses, the exact natural reservoir has not been definitively confirmed, but fruit bats are considered the most likely reservoir host based on ecological and virologic evidence. Human infections are thought to occur following contact with infected wildlife or contaminated animal tissues, after which human-to-human transmission can sustain outbreaks.
Transmission between humans occurs through direct contact with the blood, body fluids, or tissues of an infected person, as well as contaminated surfaces and medical equipment. Individuals are not thought to be contagious before symptoms develop. Healthcare settings, caregiving activities, and funeral practices involving contact with the deceased have historically played important roles in transmission during outbreaks.
MedicalResearch.com: What are the clinical symptoms and course?
Response: The clinical presentation of Bundibugyo virus disease is similar to that seen with other forms of Ebola virus disease. Symptoms typically begin abruptly and may include fever, fatigue, headache, muscle aches, sore throat, and gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain.
As the illness progresses, some patients develop severe dehydration, liver and kidney dysfunction, shock, and bleeding manifestations, although bleeding is less common than many people assume. The disease severity can vary considerably, with some patients experiencing relatively milder illness while others develop life-threatening complications.
Supportive care remains the cornerstone of treatment and includes aggressive fluid and electrolyte management, treatment of secondary infections, oxygen support when needed, and management of organ dysfunction. Early recognition and high-quality supportive care can substantially improve survival.
MedicalResearch.com: Why do outbreaks appear to occur sporadically and primarily in Central Africa?
Response: Outbreaks occur sporadically because Ebola viruses are zoonotic pathogens, meaning they are maintained in animal reservoirs and only occasionally spill over into humans. These spillover events are relatively rare and are influenced by complex ecological, environmental, and human behavioral factors that are not yet fully understood.
Central Africa contains ecosystems that support the wildlife species believed to harbor these viruses, creating opportunities for periodic spillover. Activities such as hunting, handling bushmeat, mining, agricultural expansion, deforestation, and increased human interaction with wildlife habitats may increase opportunities for exposure.
Once a spillover occurs, factors such as population movement, healthcare infrastructure, community trust, security challenges, and access to public health services influence whether a small cluster remains limited or develops into a larger outbreak.
MedicalResearch.com: How likely is it to spread to other regions?
Response: Cases may occasionally be exported to other countries through travel, particularly to neighboring nations with strong population and trade connections. We have already seen cross-border transmission into Uganda during the current outbreak.
However, widespread international transmission remains unlikely. Unlike respiratory viruses such as SARS-CoV-2, Ebola requires close contact with an infected person or their bodily fluids. This makes outbreaks much more amenable to control through traditional public health measures such as rapid diagnosis, isolation, contact tracing, infection prevention and control, and community engagement.
The greatest risk remains within affected regions and neighboring countries, which is why supporting response efforts on the ground is so critical.
MedicalResearch.com: What are suggested preventative and/or treatment measures?
Response: The most important preventive measures are rapid case identification, isolation of infected individuals, meticulous infection prevention and control practices, contact tracing, safe and dignified burials, and strong community engagement.
For healthcare workers, appropriate personal protective equipment and training are essential. Communities should be provided with clear, culturally appropriate information about symptoms, transmission risks, and when to seek care.
Unlike Zaire ebolavirus, there are currently no licensed vaccines or monoclonal antibody therapies specifically approved for Bundibugyo virus disease. As a result, treatment relies primarily on high-quality supportive care, which has been shown to significantly improve outcomes. Research is ongoing to evaluate vaccines, antivirals, and other medical countermeasures that may be effective against Bundibugyo virus.
MedicalResearch.com: Is there anything else you would like to add? Any disclosures?
Response: One important point is that while Ebola understandably generates concern, it is not a virus that spreads easily through casual contact. The tools needed to control Ebola outbreaks are well established and have been successfully used repeatedly in Africa and elsewhere. The key is rapid detection, adequate resources, community trust, and sustained support for affected countries.
The current outbreak also highlights the importance of investing in diagnostics, therapeutics, vaccines, and healthcare infrastructure before crises occur. Outbreak response is most effective when preparedness activities are maintained between emergencies rather than rebuilt during them.
Disclosure: Dr. Kuppalli is an infectious diseases physician and global health expert who has worked extensively on Ebola response efforts, including serving as Medical Director of an Ebola Treatment Unit in Sierra Leone during the 2014–2016 West Africa Ebola epidemic and supporting subsequent Ebola preparedness and response activities in Africa.
Disclaimer: The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. Products, services and providers are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on June 4, 2026 by Marie Benz MD FAAD